Krystal Biotech KRYS Stock
Krystal Biotech Price Chart
Krystal Biotech KRYS Financial and Trading Overview
| Krystal Biotech stock price | 305.68 USD |
| Previous Close | 303.06 USD |
| Open | 302.6 USD |
| Bid | 300 USD x 200 |
| Ask | 337.89 USD x 200 |
| Day's Range | 300.86 - 307.42 USD |
| 52 Week Range | 198.02 - 382.54 USD |
| Volume | 196.37K USD |
| Avg. Volume | 281.54K USD |
| Market Cap | 9.08B USD |
| Beta (5Y Monthly) | 0.648 |
| PE Ratio (TTM) | 41.64402 |
| EPS (TTM) | 7.36 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 388.22 USD |
KRYS Valuation Measures
| Enterprise Value | 8.18B USD |
| Trailing P/E | 41.64402 |
| Forward P/E | 33.214455 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 19.323778 |
| Price/Book (mrq) | 6.3262396 |
| Enterprise Value/Revenue | 17.402 |
| Enterprise Value/EBITDA | 35.713 |
Trading Information
Krystal Biotech Stock Price History
| Beta (5Y Monthly) | 0.648 |
| 52-Week Change | 49.29% |
| S&P500 52-Week Change | 9.84% |
| 52 Week High | 382.54 USD |
| 52 Week Low | 198.02 USD |
| 50-Day Moving Average | 331.52 USD |
| 200-Day Moving Average | 309.12 USD |
KRYS Share Statistics
| Avg. Volume (3 month) | 281.54K USD |
| Avg. Daily Volume (10-Days) | 407.09K USD |
| Shares Outstanding | 29.63M |
| Float | 23.65M |
| Short Ratio | 11.26 |
| % Held by Insiders | 10.64% |
| % Held by Institutions | 101.82% |
| Shares Short | 3.04M |
| Short % of Float | 16.80% |
| Short % of Shares Outstanding | 10.28% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 47.90% |
| Operating Margin (ttm) | 55.86% |
| Gross Margin | 94.27% |
| EBITDA Margin | 48.72% |
Management Effectiveness
| Return on Assets (ttm) | 10.06% |
| Return on Equity (ttm) | 17.49% |
Income Statement
| Revenue (ttm) | 470.02M USD |
| Revenue Per Share (ttm) | 16 USD |
| Quarterly Revenue Growth (yoy) | 30.19% |
| Gross Profit (ttm) | 443.12M USD |
| EBITDA | 229.03M USD |
| Net Income Avi to Common (ttm) | 225.17M USD |
| Diluted EPS (ttm) | 7.36 |
| Quarterly Earnings Growth (yoy) | -20.50% |
Balance Sheet
| Total Cash (mrq) | 911.85M USD |
| Total Cash Per Share (mrq) | 30.77 USD |
| Total Debt (mrq) | 8.59M USD |
| Total Debt/Equity (mrq) | 0.6 USD |
| Current Ratio (mrq) | 7.892 |
| Book Value Per Share (mrq) | 48.449 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 323.93M USD |
| Levered Free Cash Flow (ttm) | 221.59M USD |
Profile of Krystal Biotech
| Country | United States |
| State | PA |
| City | Pittsburgh |
| Address | 2100 Wharton Street |
| ZIP | 15203 |
| Phone | 412 586 5830 |
| Website | https://www.krystalbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 295 |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Q&A For Krystal Biotech Stock
What is a current KRYS stock price?
Krystal Biotech KRYS stock price today per share is 305.68 USD.
How to purchase Krystal Biotech stock?
You can buy KRYS shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Krystal Biotech?
The stock symbol or ticker of Krystal Biotech is KRYS.
Which industry does the Krystal Biotech company belong to?
The Krystal Biotech industry is Biotechnology.
How many shares does Krystal Biotech have in circulation?
The max supply of Krystal Biotech shares is 29.63M.
What is Krystal Biotech Price to Earnings Ratio (PE Ratio)?
Krystal Biotech PE Ratio is 41.53260800 now.
What was Krystal Biotech earnings per share over the trailing 12 months (TTM)?
Krystal Biotech EPS is 7.36 USD over the trailing 12 months.
Which sector does the Krystal Biotech company belong to?
The Krystal Biotech sector is Healthcare.
Krystal Biotech KRYS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25366.09 USD — |
-0.39
|
8.86B USD — | 25068.28 USD — | 25597.23 USD — | — - | 8.86B USD — |
|
US Tech Global Market Composite
NQGM
US
|
1958.3 USD — |
-2.44
|
— — | 1956.35 USD — | 1991.22 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7247.55 USD — |
-2.3
|
— — | 7246.35 USD — | 7373.62 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1372.96 USD — |
-1.99
|
— — | 1372.67 USD — | 1394.6 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3026.97 USD — |
-1.72
|
— — | 3024.87 USD — | 3065.71 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
